Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION 14 May 2025, 18:00 CEST Ghent, Belgium, 14 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that in the context of contributions in kind of certain receivables...
Read More
PRESS RELEASE REGULATED INFORMATION 8 May 2025, 18:00 pm CEST Ghent, Belgium – 8 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to...
Read More
PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION 7 May 2025,18:00 pm CEST Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a second subscription request notice in...
Read More
PRESS RELEASE REGULATED INFORMATION 28 April 2025,18:00 pm CEST Ghent, Belgium, 28 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by...
Read More
PRESS RELEASE REGULATED INFORMATION 25 April 2025, 18:00 pm CEST Ghent, Belgium – 25 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to...
Read More
Publication of Annual Report 2024 PRESS RELEASE REGULATED INFORMATION 22 April 2025, 18:00 pm CEST Ghent, Belgium – 22 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today invites the holders of securities...
Read More
PRESS RELEASE REGULATED INFORMATION 8 April 2025, 18:00 CEST Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that, in the context of a contribution in kind of a EUR...
Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 18 March 2025, 07:00 CET alfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial launch planned for mid Q3 2025 DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure”...
Read More
PRESS RELEASE REGULATED INFORMATION 10 February 205, 17:30 CET Ghent, Belgium – 10 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities...
Read More
PRESS RELEASE REGULATED INFORMATION 3 February 2025, 20:45 CET Ghent, Belgium – 3 February 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications in relation to the entities listed...
Read More
1 2 3 10

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES